Kornimate/medical-research-clean huggingface dataset:
neurobiological basis of response to vyvanse in adults with adhd: an fmri study of brain activation

Conditions: ADHD

Summary: the purpose of this study is to determine the effects of vyvanse, an fda approved medication used in the treatment of attention deficit hyperactivity disorder (adhd), on brain activity in adults with attention-deficit hyperactivity disorder (adhd). participants may qualify for participation in this study because they have adhd and are willing to participate in two functional magnetic resonance imaging (fmri) scans and receive vyvanse for treatment of their symptoms. another purpose of this study is to collect and bank samples of blood for research to examine how genes influence brain activation seen during the brain scans. the study also seeks to find out whether certain genes are related to adhd. participants' entire genetic makeup will not be determined from this sample.


Eligibility criteria:
inclusion criteria: * primary dsm-iv-tr diagnosis of adult adhd (inattentive, hyperactive-impulsive or combined subtype), established via the acds v1.2. * must be between 18-55 years, inclusive. * provides written informed consent. exclusion criteria: * lifetime or current diagnosis of bipolar disorder, schizophrenia or schizoaffective disorder. * current diagnosis of comorbid major depressive disorder, anxiety disorder or dysthymia or any controlled (i.e. requires pharmacological treatment) comorbid diagnosis. participants with uncontrolled depressive or anxiety disorders may participate if, in the opinion of the principal investigator, the disorder will not confound the results of efficacy or safety assessments, increase risk to the participant or lead to difficulty complying with the protocol. * meets current dsm-iv-tr criteria for alcohol or any non-alcohol substance abuse or dependence disorder. * have organic brain disease (such as dementia) or traumatic brain injury residua. have a history of seizure disorder (other than febrile seizures) or participants who have taken (or are currently taking) anticonvulsants for seizure control. * females who are currently pregnant or breast feeding, and women of child-bearing potential who are not currently using an adequate form of birth control. * participants with clinically significant abnormalities in ecg results that are deemed exclusionary in the opinion of the principal investigator will not be allowed in the trial. * participants who work the night shift or another schedule that would preclude beginning the daily dose of study medication in the morning. * participants with a positive urine drug result at screening. * medical conditions limiting participation in the study. * documented history of intolerance or non-responsivity to methylphenidate or amphetamines. * have a medical condition that would, in the opinion of the study physician, make participation medically hazardous. * adhd, not otherwise specified * history of surgery involving metal implants, metal fragments in the eyes, braces, or a pacemaker.

Keywords: attention deficit hyperactivity disorder adhd fmri imaging vyvanse stimulant medication treatment clinical trial adult
duodenostomy to treat duodenal perforation

Conditions: The Focus of Study is to Elucidate Which Are the Factors Requiring the Duodenostomy and Which Postoperative Course is for These Patients

Summary: in this study the investigators focused on duodenal perforations, requiring a tube duodenostomy and have analyzed the main features, that have influenced the surgical choices. five patients were enrolled. most of duodenal perforations can successfully be managed by simple repair, while complicated procedures are needed for complex injuries. tube duodenostomy is a damage control procedure, for large duodenal perforations when further repair techniques are not recommended due to the duodenal damage, hemodynamic instability of the patient or the absence of surgical expertise for complex reconstruction.


Eligibility criteria:
inclusion criteria: * excessive size of perforation * extreme presence of intra-abdominal infections. exclusion criteria: * patients treated by medical therapy, endoscopic techniques, o surgical approaches

Keywords: duodenostomy duodenal perforation emergency surgery
nimotuzumab in combined with chemoradiotherapy to treat the newly diagnosed diffuse intrinsic pontine glioma in children

Conditions: Diffuse Intrinsic Pontine Glioma

Summary: this is a prospective, open-label, single arm, multicenter clinical study. the purpose of the study is to evaluate the clinical efficacy and safety of combination nimotuzumab with concurrent radiochemotherapy in children with newly diagnosed diffuse intrinsic pontine glioma(dipg).

this clinical study is designed as a prospective, open-label, single arm, multicenter study to evaluate the clinical efficacy and safety of combination nimotuzumab with concurrent radiochemotherapy in children with newly diagnosed diffuse intrinsic pontine glioma(dipg). the main endpoint is objective response rate, 1-year overall survival rate is also observed.

Eligibility criteria:
inclusion criteria: 1. voluntary and sign a consent form; 2. age 3-15 years old, gender unlimited; 3. histology or imaging diagnosed as diffuse intrinsic pontine glioma, patients haven't received any anti-tumor treatment; 4. according to the rano criteria, at least one measurable lesion; 5. before enrollment, the results of laboratory examination are in accordance with: blood routine test: platelet count ≥ 100 × 10\^9/l; absolute neutrophil count ≥ 1.5 × 10\^9/l or leukocyte count ≥ 3.0 × 10\^9/l; hemoglobin ≥ 90g/l; blood biochemistry: aspartate aminotransferase#ast# ≤ 3 ×upper limit of normal#uln#; alanine aminotransferase#alt# ≤ 3 × uln; total bilirubin ≤ 1.5 × uln; serum creatinine ≤ 1.5 × uln; 6. lansky score ≥ 60; 7. expected survival time ≥ 3 months; 8. fertile subjects are willing to take contraceptive measures during the study period. exclusion criteria: 1. recurrent dipg; 2. have received any other anti-tumor treatment for dipg, including surgical treatment (except biopsy), chemotherapy, radiotherapy, targeted drugs, immunotherapy, etc; 3. uncontrollable infection, epilepsy and / or hypertension and / or hyperglycemia; 4. human immunodeficiency virus #hiv# infection or active hepatitis b infection or hepatitis c infection; 5. active hemorrhage found by ct or mri before inclusion and / or inability to carry out ct and mri examination; 6. major operation (except biopsy) were performed within four weeks before inclusion; 7. decompensated heart failure (nyha grades iii and iv), unstable angina, acute myocardial infarction, persistent and clinically significant arrhythmia within three months of inclusion; 8. have other malignant tumor history; 9. known allergy to nimotuzumab, temozolomide or its analogues or any component of the prescription; 10. unable to tolerate radiotherapy; 11. other reasons that are not suitable to participate in this study according to the researcher's judgment.

Keywords: nimotuzumab temozolomide dipg
whitsundays (nasal) mask take home study (90 days)

Conditions: Obstructive Sleep Apnea

Summary: the goal of this multi-site, prospective, randomized, double arm study without blinding is to test the usability of the whitsundays mask system at home by patients with obstructive sleep apnea. the main questions it aims to answer are: * how the whitsundays masks performs in the home environment * what is the subject's first impression of the whitsundays mask and what is their preference compared to their own mask * what is the difference between the subject's objective therapy data when using the whitsundays mask compared to their own mask * is there wear and tear of the whitsundays mask and how frequently do the cushions need replacement participants will be asked to use the whitsundays mask for 90 days, answer questionnaires about the initial impression of the mask, the performance of the mask, and their preference compared to their own mask. researchers will compare one group of subjects who will be provided with cushion replacements to another group who will only be provided with cushion replacements upon request to determine the need for cushion replacement, its frequency, and the reasons for cushion replacement during home usage.


Eligibility criteria:
inclusion criteria: * patients willing to give written informed consent * patients who can read and comprehend english * patients who ≥ 18 years of age * patients being treated for osa with a pap device for ≥ 6 months * patients currently using a resmed pap device (s9, airsense 10 \& airsense 11) compatible with airview (with cellular data connectivity and has been sending device data to the cloud) * patients currently using resmed airfit n30i or philips dreamwear™ nasal * patients who are willing to try the prototype mask for up to 90 nights * patients who are willing to take photos of the prototype mask every 2 weeks for the duration of the study * patients who reside in the usa and intend to stay in the usa for the next 6 months * patients with access to the internet (such as a smartphone or laptop) to complete online surveys exclusion criteria: * patients using bilevel flow generators * patients who are or may be pregnant * patients with a preexisting lung disease/condition that would predispose them to pneumothorax (for example: copd, lung cancer; fibrosis of the lungs; recent (\< 2years) case of pneumonia or lung infection; lung injury. * if you are pregnant or planning to become pregnant * patients believed to be unsuitable for inclusion by the researcher
evaluation of pco2 and po2 values in the pulmonary artery and superior vena cava

Conditions: Heart Diseases

Summary: the study is about comparing blood samples obtained from the superior vena cava and the pulmonary artery. the investigators will compare the values of pco2 and po2 from these two sites, in order to see if exists a pco2 gap and a po2 gap, different from zero. moreover the investigators want to find out if these gaps are related with changes in the cardiac output, the hematocrit or if they can predict post operative dysfunctions. blood samples will be taken at six different times as scheduled by the protocol. along with the two venous blood samples, an arterial blood sample will be taken too, from a radial of femoral artery catheter.


Eligibility criteria:
inclusion criteria: * age \> 18 years * patient undergoing cardiac surgery with extracorporeal circulation * hemodynamic monitoring with a central venous catheter and a swan ganz catheter placed in the internal left giugulare vein exclusion criteria: * severe tricuspid insufficiency * ef \< 50% * sofa score \>1 in at least one of all the criteria
evaluation of ptb screening in anc in lusaka, zambia

Conditions: Pulmonary Tuberculosis

Summary: this is a pilot pulmonary tb screening program done in three antenatal care clinics in lusaka, zambia to determine the prevalence of culture-confirmed pulmonary tuberculosis and to determine the sensitivity and specificity of symptom-based tb screening.

5000 pregnant women attending antenatal clinics will be evaluated by piloting a tb symptom questionnaire as part of the general health screening done at each visit. due to the atypical and subclinical presentation of tb in hiv infected patients, culture will be performed on all hiv-infected pregnant women, with or without symptoms, and on all symptomatic hivnegative women. referrals for tb treatment in accordance with current national guidelines will be offered.

Eligibility criteria:
inclusion criteria: * pregnant women * 18 years or older * hiv-negative women with any tb symptoms or hiv-infected women regardless of tb symptoms * attending first anc visit at one of program clinics exclusion criteria: * hiv negative without any tb symptoms

Keywords: tuberculosis hiv pregnancy
telephone paramedical support prior to the radiotherapy simulation scanner for patients with prostate cancer

Conditions: Radiotherapy; Prostate Cancer

Summary: the goal of this clinical trial is to evaluate the impact of a phone call before the simulation ct scan in management of care of patients with prostate cancer.

after being informed about the study, all patients who have given written informed consent and who met eligibility requirement will be randomized in a simple blind manner ( investigator) in a 1:1 ration. the main question it aims to answer is : does a phone call before the simulation ct scan has an effectiveness on patients compliance of the recommendations and therefore on obtaining quality images. there is no additional risk of patients involvement.

Eligibility criteria:
inclusion criteria: * adult * patient coming for prostate cancer treatment with or without lymph node irradiation * minimum of 48 hours between the onco radiotherapist and the ct scan * signed a written informed consent form * affiliated to the social security system exclusion criteria: * patient not understanding french * patient not reachable by phone * individual of full age deprived of liberty or placed under a legal protection measure

Keywords: paramedical phone call
glycemic optimization on discharge from the emergency room

Conditions: Diabetes Mellitus

Summary: continuous glucose monitors can help people with diabetes avoid blood sugar levels that are either dangerously high or low. this study evaluates whether continuous glucose monitoring after discharge from the emergency room can help people with type 1 or type 2 diabetes avoid repeat emergency room visits, achieve improved blood sugar control, and feel less distressed about managing their diabetes.


Eligibility criteria:
inclusion criteria: * seen in the emergency department for hypo- or hyperglycemia * either an existing diabetes center patient or a new referral * type 1 or type 2 diabetes * able to provide informed consent * fluent in english or spanish exclusion criteria: * current cgm use * need for hospital admission * upcoming ct or mri within 2 weeks * pregnancy * altered mental status * not appropriate for diabetes center follow up * prisoners
expanded access to venetoclax

Conditions: Chronic Lymphocytic Leukemia (CLL); Multiple Myeloma; Acute Myeloid Leukemia (AML); Non-Hodgkin's Lymphoma; Acute Lymphoblastic Leukemia (ALL); Amyloidosis; Plasma Cell Leukemia

Summary: this is an expanded access program (eap) for eligible participants. this program is designed to provide access to venetoclax prior to approval by the local regulatory agency. availability will depend on territory eligibility. a medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.


Eligibility criteria:
inclusion criteria: * the participant must not be eligible for a venetoclax clinical trial. * pediatric participants may be evaluated on a case by case basis.

Keywords: expanded access pre-approval access compassionate use special access program named patient basis special access scheme
a study of verve-101 in patients with familial hypercholesterolemia and cardiovascular disease

Conditions: Heterozygous Familial Hypercholesterolemia; Atherosclerotic Cardiovascular Disease; Hypercholesterolemia

Summary: vt-1001 is an open-label, phase 1b, single-ascending dose study that will evaluate the safety of verve-101 administered to patients with heterozygous familial hypercholesterolemia (hefh), atherosclerotic cardiovascular disease (ascvd), and uncontrolled hypercholesterolemia. verve-101 uses base-editing technology designed to disrupt the expression of the pcsk9 gene in the liver and lower circulating pcsk9 and ldl-c in patients with established ascvd due to hefh. this study is designed to determine the safety and pharmacodynamic profile of verve-101 in this patient population.


Eligibility criteria:
inclusion criteria: * male and/or female participants 18 up to 75 years at time of signing of informed consent * female participants not of child-bearing potential * diagnosis of hefh * established ascvd exclusion criteria: * active or history of chronic liver disease * current treatment with pcsk9 monoclonal antibody therapy * current or past treatment with inclisiran * clinically significant or abnormal laboratory values as defined by the protocol

Keywords: verve-101 familial hypercholesterolemia cardiovascular disease dose escalation gene editing base editing
efficacy of tacs for treatment of auditory hallucinations in refractory schizophrenia

Conditions: Schizophrenia

Summary: the aim of this study is to evaluate the feasibility and efficacy of transcranial alternating current stimulation (tacs) as an add-on treatment for auditory hallucinations in refractory schizophrenia. meanwhile, we aim to evaluate the effect of tacs on cognitive function of schizophrenia patients. we hypothesize tacs would improve refractory auditory hallucination symptoms in schizophrenia by regulating the gamma frequency band of temporal lobe。

this is a randomized, double-blind, sham-controlled study to detect the effect of tacs for treatment of refractory auditory hallucinations in schizophrenia. 50 participants were randomly assigned 1:1 to tacs group or sham-control group. for both active and sham group, daily tacs sessions were scheduled in a 5-day sequence for four consecutive weeks, and each session lasted 20minutes. based on the original and stable medication, active participants were administered 2 ma alternating current delivered with gamma frequency, delivered over the temporal lobe, while controls received sham stimulations with the same protocol. scale assessments are performed at baseline, week 2, week 4 and week 6. collection of blood took place at baseline, week 4 and week 6.

Eligibility criteria:
inclusion criteria: 1. eligible participants aged 18-70 with dsm-5-defined schizophrenia or schizophrenia-like disorder. 2. duration of illness \> 12 weeks. 3. being clinically stable and on an adequate therapeutic dose of antipsychotics for at least 8 weeks prior to enrolment. 4. junior high school education or above 5. after treatment with ≥ 2 different antipsychotics (greater than the equivalent dose of chlorpromazine 600mg), the curative effect was poor (cgi ≥ 4 points or the panss score reduction rate since this treatment was less than 20%) 6. agreement to participate in the study and provide the written informed consent. exclusion criteria: 1. having unstable medical conditions, current psychiatric comorbidity or active substance use disorder (in exception to caffeine and/or tobacco) 2. having serious physical diseases or nervous system diseases; 3. having any brain device / implant, including cochlear implant and aneurysm clip; 4. having a history or family history of autoimmune diseases or immune diseases; 5. pregnancy or breastfeeding at enrollment; 6. skin lesions on scalp at the area of electrode application.
trauma equivalency study of the cora® and teg® 5000 systems

Conditions: Trauma

Summary: this study is being performed to obtain data about the cora system when used in a trauma clinical setting. the cora analyzer is a new device that is currently being tested in trauma clinical applications and is not yet cleared for this purpose by the food and drug administration (fda) for sale in the united states.

the purpose of the study is to validate the cora system by comparing the results of this test to that of the standard of care device called the teg 5000 system. both systems evaluate hemostasis, a highly complex and interactive process involving many protein and cellular elements, especially platelets, occurring in a series of interrelated phases, which results in either normal hemostasis or a tendency toward bleeding or clotting complications. the study protocol specifies testing using multiple reagents which are similar for both the cora and tg 5000 systems. tests are run in duplicate on blood samples taken from patients undergoing treatment for injuries and trauma. following the protocol defined in clsi standard ep09-a2, equivalence between the two systems will be demonstrated if the conclusions from the standard section 7, interpreting results and comparing to internal performance criteria, are found to be acceptable. all blood samples drawn for this study will use venous blood. only citrated or heparinized whole blood samples are used. all samples are tested twice (run in duplicate). quality control procedures are run on both instruments at a frequency specified by the manufacturers. results obtained from this testing are not used to make treatment decisions.

Eligibility criteria:
inclusion criteria: * 18 years of age and older * complete patient history including age, race, gender and type of trauma should be documented exclusion criteria: * patients under the age of 18 * native whole blood will not be used in this study

Keywords: focus testing performance cora hemostasis system
a study to evaluate the safety and efficacy of ng101 in adult participants receiving a glp-1 agonist

Conditions: Overweight and Obesity; Healthy

Summary: adult participants with bmi between 22 - 35 kg/m2 will be enrolled and randomized to receive either ng101 (20 mg bid) or placebo for 5 days beginning on day 1. on day 2, all participants will receive a single subcutaneous injection of a glp-1 agonist (semaglutide). participants will remain at the clinical research unit for the duration of the treatment period. the goal of this clinical trial is to evaluate the safety and efficacy of ng101 compared to placebo, when also administered along with a glp-1 agonist, in the management of gastrointestinal side effects commonly associated with glp-1 agonists for overweight or obesity. adverse event information will be collected. gi-specific questionnaires will be used to capture additional details if gi-related adverse events are reported.


Eligibility criteria:
inclusion criteria: * healthy adult * male or female * bmi between 22 - 35 kg/m2 at screening exclusion criteria: * presence or history of illness that might confound the results of the study or pose an - * history of presence of gastroparesis, gallbladder disease, acute or chronic pancreatitis, or surgery of the abdomen * history or presence of type 1 or type 2 diabetes
effects of cognitive training on children with attention deficit hyperactivity disorder

Conditions: Attention Deficit Hyperactivity Disorder

Summary: using a single blind, randomized controlled design to study the additional therapeutic effects of cognitive training on traditional rehabilitation programs for children with attention deficit hyperactivity disorder and developmental delays.

a total of 30 children with attention deficit hyperactivity disorder and developmental delays who are receiving traditional rehabilitation programs will be enrolled. the participants will be randomized into two groups, including study group (traditional rehabilitation program with additional cognitive training: 2 times per week, 15 min per session, a total of 24 sessions) and control group (traditional rehabilitation program without additional cognitive training). memory related functions, quality of life, and physical function evaluations will be performed at baseline, 3 months and 6 months later, respectively. evaluator will be blinded to the group's classification during the whole course of study.

Eligibility criteria:
inclusion criteria: * children diagnosed with attention deficit hyperactivity disorder with developmental delay receiving regular rehabilitation programs intelligence quotient 70 or greater exclusion criteria: * age less than 4 years or elder than 8 years children diagnosed with attention deficit hyperactivity disorder receiving regular rehabilitation programs intelligence quotient less than 70

Keywords: cognitive training developmental delay children therapeutic effect